14-O-phosphonooxymethyltriptolide

Known as: Minnelide 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
02420102016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
OBJECTIVES Pancreatic cancer has a 5-year survival rate of less than 5%, partly because of limited chemotherapeutic options… (More)
Is this relevant?
2014
2014
INTRODUCTION Sorafenib is the only drug approved by the Food and Drug Administration for metastatic hepatocellular carcinoma (HCC… (More)
Is this relevant?
2014
2014
PURPOSE Pancreatic adenocarcinoma is the fourth leading cause for cancer-related mortality with a survival rate of less than 5… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
OBJECTIVES The incidence of high-risk human papillomavirus (HR-HPV) head and neck squamous cell carcinoma (HNSCC) continues to… (More)
Is this relevant?
2013
2013
Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest malignancies, is resistant to current chemotherapies. We previously… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Pancreatic cancer, the fourth most prevalent cancer-related cause of death in the United States, is a disease with a dismal… (More)
Is this relevant?
2013
2013
Pancreatic cancer is one of the most lethal human malignancies, with an all-stage 5-year survival of <5%, mainly due to lack of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Osteosarcoma is the most common bone cancer in children and adolescents with a 5-year survival rate of about 70%. In this study… (More)
Is this relevant?
2013
2013
BACKGROUND Minnelide, a pro-drug of triptolide, has recently emerged as a potent anticancer agent. The precise mechanisms of its… (More)
Is this relevant?
2012
2012
Pancreatic cancer is one of the most lethal human malignancies with an all-stage 5-year survival frequency of <5%, which… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?